APA (7th ed.) Citation

Uppal, G., Rajan, S. S., Bhandarkar, A., Babhulkar, S., & Dhandapani, A. D. In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review. Cambridge University Press.

Chicago Style (17th ed.) Citation

Uppal, Gaurav, Sathyan Soundara Rajan, Akhila Bhandarkar, Sneh Babhulkar, and Asha Devi Dhandapani. In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review. Cambridge University Press.

MLA (9th ed.) Citation

Uppal, Gaurav, et al. In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review. Cambridge University Press.